For many facing a diagnosis of diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer, the standard treatment – an antibody combined with four chemotherapy drugs – offers a path to remission. But roughly three in ten patients don’t respond to this regimen, and the intense chemotherapy carries significant risks, particularly heart damage, for older individuals who comprise a large portion of those diagnosed. Now, research suggests a potential way to predict which patients might not benefit from this frontline treatment, offering a chance to explore less toxic alternatives earlier in the course of their illness.
A new study, published in Scientific Reports, reveals that analyzing immune cell activity in blood samples could identify patients likely to have a poor response to treatment. The research, notably conducted in pet dogs with DLBCL, builds on the understanding that the immune system plays a critical role in fighting cancer and that certain immune signatures can indicate a cancer’s vulnerability – or resistance – to therapy. This approach mirrors the growing field of “liquid biopsies” used in both human and veterinary oncology, offering a less invasive alternative to traditional tumor biopsies.
Immune Signatures and Treatment Response in Canine Lymphoma
Researchers from Cummings School of Veterinary Medicine at Tufts University and UMass Chan Medical School analyzed blood samples from dogs participating in a clinical trial testing new DLBCL treatment regimens. These regimens combined a canine antibody similar to those used in human medicine with a lower dose of doxorubicin, a common chemotherapy drug, followed by one of three experimental immune-boosting therapies. Two of these immunotherapies are currently being evaluated in human clinical trials, highlighting the potential for translational research between species.
The team didn’t focus on the tumor itself, but instead examined gene activity within circulating immune cells at multiple points during treatment: before starting, seven days in, just before immunotherapy, at the end of the cycle, and either upon cancer recurrence or 400 days post-treatment if the dog remained cancer-free. By comparing gene activity patterns between dogs with long-term survival and those with rapid relapse, researchers identified key indicators of treatment success.
“Many of today’s cancer treatments are designed to boost the immune system so it can help eliminate the tumor,” explained Jillian Richmond, an assistant professor of comparative pathobiology at Cummings School and a senior author on the study. “What we found was that certain immune-related genes circulating in the blood were linked to either a good or a poor response to treatment.”
Genes Linked to Survival and Resistance
Specifically, the study found that activity in two genes, CD1E and CCL14, correlated with longer survival times. CD1E aids in delivering signals that enhance T cell recognition of cancer cells, while CCL14 acts as a chemical signal attracting immune cells to the tumor site. These findings suggest these genes could serve as biomarkers for a more effective immune response.
Interestingly, the type of immunotherapy administered didn’t seem to be the deciding factor. Instead, the study indicated that the state of the immune system *before* treatment began was more predictive of outcome. An “exhausted” immune system, already depleted and less responsive, appeared to limit the effectiveness of even the most promising therapies.
Perhaps surprisingly, the researchers also discovered a link between interferon-stimulated genes and poorer outcomes. Interferons are cytokines – proteins used by immune cells to communicate – and have historically been considered protective in cancer treatment. However, this study suggests that in DLBCL, certain interferon signals may inadvertently help cancer cells survive and proliferate. “We suspect that, they may be helping cancerous blood cells survive or continue to rapidly reproduce,” Richmond stated.
Further analysis identified three additional genes – TBHD, NPNT, and ISG20 – whose activity within the first week of treatment predicted a poor prognosis. Heather Gardner, a professor at Cummings School and co-senior author, has developed a laboratory test to quickly detect elevated activity in these genes, potentially flagging high-risk patients early on.
Translating Findings to Human Cancer Care
The implications of this research extend beyond veterinary medicine. Cheryl London, a professor in comparative oncology at Cummings School and another co-senior author, is planning a follow-up study to determine if using this blood test to guide treatment decisions can improve survival rates in dogs with lymphoma. “Our long-term goal is to leverage the data we are generating in dogs with lymphoma to develop new diagnostics and therapeutic combinations that can be successfully translated into human lymphoma patients to reduce treatment-related toxicities and improve outcomes,” London said.
The ability to identify non-responders early in treatment could be transformative for patients with DLBCL. It would allow clinicians to avoid unnecessary exposure to harsh chemotherapy and explore alternative, potentially less toxic, treatment options sooner. This is particularly important for older patients, who are more vulnerable to the side effects of intensive chemotherapy, according to the American Cancer Society.
While further research is needed to validate these findings in human populations, this study represents a significant step toward personalized cancer treatment. The promise of a simple blood test to predict treatment response offers a beacon of hope for those battling this aggressive form of lymphoma.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The research team is continuing to analyze data and refine the predictive model. The next step will involve prospective studies in human patients to confirm the accuracy and clinical utility of these immune signatures. Share your thoughts and experiences in the comments below.
Worth a look
